Philip Komarnitsky
Seminars
Wednesday 27th January 2027
From First-in-Human Studies to Clinical Validation: Advancing Non- Degrading Molecular Glues into Patients
3:30 pm
- Advancing a novel non-degrading molecular glue from discovery through clinical development, demonstrating how induced-proximity therapeutics can generate therapeutic benefit beyond protein degradation
- Evaluating safety, pharmacokinetics, pharmacodynamic biomarkers, and early signals of activity from first-in-human studies to establish the clinical potential of nondegrading molecular glue therapies
- Sharing key translational and clinical learnings from programme progression to help de-risk future molecular glue development efforts and accelerate the path from innovative biology to patient impact
Wednesday 27th January 2027
Panel Discussion: De-Risking Molecular Glue Development: What Does It Take to Build a Clinically and Commercially Successful Programme?
4:00 pm
- How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
- What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
- As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?
